Pfizer Inc. (PFE)

43.73
0.64 1.40
NYSE : Health Technology
Prev Close 44.37
Open 43.89
Day Low/High 43.75 / 44.24
52 Wk Low/High 33.20 / 45.81
Volume 9.41M
Avg Volume 20.46M
Exchange NYSE
Shares Outstanding 5.86B
Market Cap 260.86B
EPS 3.60
P/E Ratio 11.90
Div & Yield 1.36 (3.05%)
Stocks to Buy, Stocks to Dump in This Volatile Market

Stocks to Buy, Stocks to Dump in This Volatile Market

Common sense says get more defensive.

Pfizer Presents Overall Survival Data From PALOMA-3 Trial Of IBRANCE® (palbociclib) In Patients With HR , HER2- Metastatic Breast Cancer

Pfizer Presents Overall Survival Data From PALOMA-3 Trial Of IBRANCE® (palbociclib) In Patients With HR , HER2- Metastatic Breast Cancer

Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+),...

Pfizer Confirms to Cut Workforce by 2%

Pfizer Confirms to Cut Workforce by 2%

Pfizer is looking to cut some 1,800 workers during 2019 amid a leadership shakeup.

Trump-FOMC Blame Game Is Pointless; Safety Stocks for Crashes -- ICYMI

Trump-FOMC Blame Game Is Pointless; Safety Stocks for Crashes -- ICYMI

Here's what you need to know now for Thursday, Oct. 11.

Dow Ends Off More Than 500, Two-Day Loss Tops 1,375

Dow Ends Off More Than 500, Two-Day Loss Tops 1,375

Fresh selling hit stocks into the close Thursday, pushing the Dow down more than 500 points for a two-day loss of more than 1,375.

The New #11 Most Shorted Dow Component: Pfizer

The New #11 Most Shorted Dow Component: Pfizer

The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Pfizer Announces Executive Leadership Team

Pfizer Announces Executive Leadership Team

Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new role effective January 1, 2019.

It's Been a Revolving Door in the C-Suite Lately

It's Been a Revolving Door in the C-Suite Lately

Changes in the C-Suite seem to be the norm lately. Between retirements and impatient shareholders, Wall Street has had to deal with a lot of movement. Watch now to see who's coming and going!

The 2018 C-Suite Shuffle Continues; Honeywell Spins Automation Unit -- ICYMI

The 2018 C-Suite Shuffle Continues; Honeywell Spins Automation Unit -- ICYMI

Here's what you need to know now for Monday, Oct. 1.

Dow, S&P 500 End Higher on New Nafta Deal; Nasdaq Slips

Dow, S&P 500 End Higher on New Nafta Deal; Nasdaq Slips

The Dow Industrials and S&P 500 index ended higher Monday while the Nasdaq slipped after Canada and the U.S. agreed on a revised trade pact.

Tesla Produced A Record Number of Vehicles in Q3, Report Says: LIVE MARKETS BLOG

Tesla Produced A Record Number of Vehicles in Q3, Report Says: LIVE MARKETS BLOG

Tesla produced 80,000 vehicles in the quarter, according to electrek.

Pfizer Says CEO Ian Read to Retire; COO Albert Bourla Will Lead Group From 2019

Pfizer Says CEO Ian Read to Retire; COO Albert Bourla Will Lead Group From 2019

Pfizer shares are down slightly following news that long-serving CEO Ian Read will step down by the end of the year.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Pfizer Announces CEO Succession

Pfizer Announces CEO Succession

Pfizer Inc. (NYSE:PFE) today announced its Board of Directors has unanimously elected Dr.

Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend

Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend

The board of directors of Pfizer Inc. today declared a 34-cent fourth-quarter 2018 dividend on the company's common stock, payable December 3, 2018, to shareholders of record at the close of business on November 9, 2018.

Pfizer Becomes #14 Most Shorted Dow Stock, Replacing Travelers Companies

Pfizer Becomes #14 Most Shorted Dow Stock, Replacing Travelers Companies

The most recent short interest data has been released for the 09/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Astellas Receives Positive CHMP Opinion For XTANDI® (enzalutamide) For Adult Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Astellas Receives Positive CHMP Opinion For XTANDI® (enzalutamide) For Adult Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)

Pfizer Granted FDA Breakthrough Therapy Designation For 20-Valent Pneumococcal Conjugate Vaccine For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Granted FDA Breakthrough Therapy Designation For 20-Valent Pneumococcal Conjugate Vaccine For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for the prevention of invasive disease and...

Pfizer Invites Public To View And Listen To Webcast Of October 30 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of October 30 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

New Sub-group Analyses From The Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented At 2018 HFSA Annual Scientific Meeting

New Sub-group Analyses From The Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented At 2018 HFSA Annual Scientific Meeting

Pfizer Inc. (NYSE:PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) study provide further detail on the effect of tafamidis across wild-type, hereditary, and...

Pfizer Presents Positive Phase 2 Data In Alopecia Areata During Late-Breaker Session At The 27th European Academy Of Dermatology And Venereology (EADV) Congress

Pfizer Presents Positive Phase 2 Data In Alopecia Areata During Late-Breaker Session At The 27th European Academy Of Dermatology And Venereology (EADV) Congress

Pfizer Inc. (NYSE:PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia...

Pfizer Becomes #19 Most Shorted Dow Stock, Replacing Cisco Systems

Pfizer Becomes #19 Most Shorted Dow Stock, Replacing Cisco Systems

The most recent short interest data has been released for the 08/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 16 th Annual Global Healthcare Conference on...

Pfizer Receives Breakthrough Therapy Designation From FDA For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Alopecia Areata

Pfizer Receives Breakthrough Therapy Designation From FDA For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Alopecia Areata

Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.

3 Biotech Stocks Ready to Burn Up

3 Biotech Stocks Ready to Burn Up

Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of six tranches of notes: $300,000,000 aggregate principal amount of floating rate notes due 2023 $1,000,000,000 aggregate principal amount of 3.

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies For The Treatment Of Duchenne Muscular Dystrophy

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies For The Treatment Of Duchenne Muscular Dystrophy

Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label...

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Markets were higher Tuesday after starting Tuesday's session off in the green.

New Records as Dow and Other Indexes Post Gains on Tentative Mexico Trade Deal

New Records as Dow and Other Indexes Post Gains on Tentative Mexico Trade Deal

The S&P 500 and Nasdaq set record highs as stocks rose Monday after the U.S. and Mexico reached a tentative trade agreement.

TheStreet Quant Rating: A+ (Buy)